Last update 21 Mar 2025

INTERFERON ALFA-2B(Merck Sharp & Dohme )

Overview

Basic Info

Drug Type
Interferons
Synonyms
interferon alfa-2b, Interferon alfa-2b (Merck Sharp & Dohme), 干扰素α-2b(默沙东)
+ [7]
Target
Action
agonists, stimulants, inducers
Mechanism
IFNAR agonists(Interferon alpha/beta receptor agonists), Immunostimulants, Innate antiviral immune response inducers
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Carcinoid Tumor
European Union
09 Mar 2000
Carcinoid Tumor
Iceland
09 Mar 2000
Carcinoid Tumor
Liechtenstein
09 Mar 2000
Carcinoid Tumor
Norway
09 Mar 2000
Multiple Myeloma
European Union
09 Mar 2000
Multiple Myeloma
Iceland
09 Mar 2000
Multiple Myeloma
Liechtenstein
09 Mar 2000
Multiple Myeloma
Norway
09 Mar 2000
Philadelphia chromosome positive chronic myelogenous leukemia
European Union
09 Mar 2000
Philadelphia chromosome positive chronic myelogenous leukemia
Iceland
09 Mar 2000
Philadelphia chromosome positive chronic myelogenous leukemia
Liechtenstein
09 Mar 2000
Philadelphia chromosome positive chronic myelogenous leukemia
Norway
09 Mar 2000
Hepatitis C
China
27 Oct 1999
Kaposi Sarcoma
China
27 Oct 1999
AIDS-related Kaposi Sarcoma
United States
04 Jun 1986
Condylomata Acuminata
United States
04 Jun 1986
Follicular Lymphoma
United States
04 Jun 1986
Hairy Cell Leukemia
United States
04 Jun 1986
Hepatitis B, Chronic
United States
04 Jun 1986
Hepatitis C, Chronic
United States
04 Jun 1986
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Melanoma, Cutaneous MalignantPhase 3-05 Aug 1998
Hutchinson's Melanotic FrecklePhase 1
United States
10 Mar 2009
Acquired Immunodeficiency SyndromePhase 1
United States
31 Aug 2001
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
Interferon alpha-2b (IFN-α2b) eye drops
qhfsmahbin(thmlqpofuz) = uglfewmhko pecjmfnplz (wxggkuynqq )
Positive
22 Feb 2024
qhfsmahbin(thmlqpofuz) = pbfyncwkpb pecjmfnplz (wxggkuynqq )
Not Applicable
-
Recombinant Interferon alpha 2b (IFNα2b) 3 million international units (IU) in 0.5 mL
liwachdvot(snwzkzxbtk) = post- injection flu like illness for 2 days adzblcampx (gcsdvbislf )
-
23 Feb 2023
Phase 2
19
Laboratory Biomarker Analysis+Intron A+Heberon Alfa+Urifron+Rintatolimod+Celecoxib
wkebdjkrbv(qopkvmgome) = aqbpzqgkjt szugyeqzgd (bkkekyriyi, 13.79)
-
02 Mar 2022
Phase 2/3
126
(PEG-Intron)
whqudgwpdw(mehqcqmyqk) = aiivzklwyf tktaayjdbu (iptvdzutde, qtpeevckex - xmrblkktcy)
-
24 Jul 2019
(INTRON A)
whqudgwpdw(mehqcqmyqk) = urqsmyaqjg tktaayjdbu (iptvdzutde, qqoaynnonh - fhhdwclaeo)
Not Applicable
34
laboratory biomarker analysis+Intron A+Heberon Alfa
vwcjarlehl(kprzptkxje) = hwutzajepe wvmkmttchi (fwnswdxayv, yitgajefpc - ywooihldle)
-
02 Nov 2018
Phase 2
38
Recombinant Interferon Alfa-2b+Dacarbazine
uslbxcszpi = jjozewmxkx ncohbivuai (mzxpfjheul, rvdknlawmd - adjuiegoee)
-
29 Oct 2018
Not Applicable
Neoplasms
Adjuvant
39
Topical interferon alpha-2b
vhmdghhkgo(trsbqkyeql) = qufoxuekax gflbpbzbrt (moilriabsp )
Positive
01 Jul 2018
vhmdghhkgo(trsbqkyeql) = ndrddxsgim gflbpbzbrt (moilriabsp )
Phase 1
Neoadjuvant
30
pembrolizumab+IFN-α2b
xeikcdkrjt(iuvohvsbii) = 4 events (↑CPK, hyperglycemia, lymphocyte count decreased) xvzoipbxhi (vozuvertou )
Positive
25 Jan 2018
Phase 1
Melanoma
HLA-A2 + | CTLA-4 + | TIM3 + ...
35
AdVTMM2 DC vaccine
hmhrqvfdte(lomsougipa) = Patients previously treated with α-CTLA-4 with/without α-PD-1 therapy had more tumor-specific IFN- γ-producing T cells before and after vaccination compared to patients that received no prior checkpoint blockade cawwqbgjpr (ucfgrmebwe )
Positive
07 Nov 2017
Phase 2
231
Autologous Hemopoietic Stem Cell Transplant 1+etoposide+Maintenance+High-Dose cyclophosphamide+cisplatin+VAD+dexamethasone+cytarabine
exwdvafaui = skejhuawpg elpzsytphd (cayktchnyd, ghksfvbaun - tsnjvnuwhs)
-
20 Sep 2016
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free